JLE

Epileptic Disorders

MENU

Antiepileptic drugs: evolution of our knowledge and changes in drug trials Volume 21, numéro 4, August 2019

  • [Arzimanoglou et al., 2010] Arzimanoglou A., Ben-Menachem E., Cramer J., Glauser T., Seeruthun R., Harrison M. The evolution of antiepileptic drug development and regulation. Epileptic Disord. 2010;12:3-15.
  • [Buchthal and Svensmark, 1971] Buchthal F., Svensmark O. Serum concentrations of diphenylhydantoin (phenytoin) and phenobarbital and their relation to therapeutic and toxic effects. Psychiatr Neurol Neurochir. 1971;74:117-136.
  • [Chen et al., 2018] Chen Z., Brodie M.J., Liew D., Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75:279-286.
  • [Coatsworth, 1971] Coatsworth JJ. Studies on the clinical efficacy of marketed anti-epileptic drugs. NINDS Monograph No. 12, DHEW Publication No. (NIH) 73-51. Washington, DC: US Government Printing Office,1971.
  • [Council on Pharmacy and Chemistry, 1939] Council on Pharmacy Chemistry of the American Medical Association. Dilantin sodium. JAMA. 1939;113:1734-1735.
  • [D’Ambrosio et al., 2013] D’Ambrosio R., Eastman C.L., Fattore C., Perucca E. Novel frontiers in epilepsy treatments: preventing epileptogenesis by targeting inflammation. Expert Rev Neurother. 2013;13:615-625.
  • [European Medicines Agency, 2018] European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of epileptic disorders. CHMP/EWP/566/98 Rev 3 (draft). 2018. https: //www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-epileptic-disorders-revision-3_en.pdf
  • [Franco et al., 2016] Franco V., French J.A., Perucca E. Challenges in the clinical development of new antiepileptic drugs. Pharmacol Res. 2016;103:95-104.
  • [French and Gazzola, 2011] French J.A., Gazzola D.M. New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety? Ther Adv Drug Saf. 2011;2:141-158.
  • [French et al., 2015] French J.A., Gil-Nagel A., Malerba S., Kramer L., Kumar D., Bagiella E. Time to prerandomization monthly seizure count in perampanel trials: a novel epilepsy endpoint. Neurology. 2015;84:2014-2020.
  • [Friedlander, 1986] Friedlander W.J. Putnam, Merritt, and the discovery of phenytoin. Epilepsia. 1986;27:S1-21.
  • [Gastaut, 1969a] Gastaut H. Clinical and electroencephalographical classification of epileptic seizures. Epilepsia. 1969;10:2-13.
  • [Gastaut, 1969b] Gastaut H. Classification of the epilepsies. Proposal for an international classification. Epilepsia. 1969;10:14-21.
  • [Gazzola et al., 2007] Gazzola D.M., Balcer L.J., French J.A. Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. Epilepsia. 2007;48:1303-1307.
  • [Glauser et al., 2013a] Glauser T., Ben-Menachem E., Bourgeois B. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54:551-563.
  • [Glauser et al., 2013b] Glauser T.A., Cnaan A., Shinnar S. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia. 2013;54:141-155.
  • [Greenwhich Biosciences, 2018] Greenwhich Biosciences, Inc. Epidiolex - full prescribing information. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf
  • [Gruber et al., 1962] Gruber C.M., Brock J.T., Dyken M. Comparison of the effectiveness of phenobarbital, mephobarbital, primidone, diphenylhydantoin, ethotoin, metharbital, and methylphenylethylhydantoin in motor seizures. Clin Pharmacol Ther. 1962;3:23-28.
  • [Hills and Armitage, 1979] Hills M., Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol. 1979;8:7-20.
  • [Kehne et al., 2017] Kehne J.H., Klein B.D., Raeissi S., Sharma S. The National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP). Neurochem Res. 2017;42:1894-1903.
  • [Kinnear-Wilson, 1940] Kinnear-Wilson SA. Neurology. London: Edward Arnold, 1940.
  • [Klein et al., 2015] Klein P., Schiemann J., Sperling M.R. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56:1890-1898.
  • [Klein et al., 2017] Klein B.D., Jacobson C.A., Metcalf C.S. Evaluation of cannabidiol in animal seizure models by the Epilepsy Therapy Screening Program (ETSP). Neurochem Res. 2017;42:1939-1948.
  • [Kutt et al., 1975] Kutt H., Solomon G., Wasterlain C., Peterson H., Louis S., Carruthers R. Carbamazepine in difficult to control epileptic out-patients. Acta Neurol Scand Suppl. 1975;60:27-32.
  • [Kwan and Brodie, 2000] Kwan P., Brodie M.J. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314-319.
  • [Kwan and Brodie, 2001] Kwan P., Brodie M.J. Effectiveness of first antiepileptic drug. Epilepsia. 2001;42:1255-1260.
  • [Lennox, 1940] Lennox W. Study of epilepsy in America in 1938. Epilepsia. 1940;B1:279-290.
  • [Lund, 1974] Lund L. Anticonvulsant effect of diphenylhydantoin relative to plasma levels. A prospective three-year study in ambulant patients with generalized epileptic seizures. Arch Neurol. 1974;31:289-294.
  • [Marson et al., 2005] Marson A., Jacoby A., Johnson A. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet. 2005;365:2007-2013.
  • [Mattson et al., 1985] Mattson R.H., Cramer J.A., Collins J.F. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med. 1985;313:145-151.
  • [Mattson et al., 1992] Mattson R.H., Cramer J.A., Collins J.F. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med. 1992;327:765-771.
  • [Medical Research Council, 1948] Streptomycin treatment of tuberculous meningitis. Lancet. 1948;1:582-596. Medical Research Council
  • [Merritt and Putnam, 1938] Merritt H.H., Putnam T.J. Sodium diphenyl hydantoinate in the treatment of convulsive disorders. JAMA. 1938;111:1068-1073.
  • [Mintzer et al., 2015] Mintzer S., French J.A., Perucca E. Is a separate monotherapy indication warranted for antiepileptic drugs? Lancet Neurol. 2015;14:1229-1240.
  • [Mumford and Dam, 1989] Mumford J.P., Dam M. Meta-analysis of European placebo-controlled studies of vigabatrin in drug-resistant epilepsy. Br J Clin Pharmacol. 1989;27:101S-S107.
  • [Pellock et al., 2017] Pellock J.M., Arzimanoglou A., D’Cruz O. Extrapolating evidence of antiepileptic drug efficacy in adults to children ≥2 years of age with focal seizures: The case for disease similarity. Epilepsia. 2017;58:1686-1696.
  • [Perucca, 1982] Perucca E. Pharmacokinetic interactions with antiepileptic drugs. Clin Pharmacokinet. 1982;7:57-84.
  • [Perucca, 2006] Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61:246-255.
  • [Perucca, 2008] Perucca E. Designing clinical trials to assess antiepileptic drugs as monotherapy: difficulties and solutions. CNS Drugs. 2008;22:917-938.
  • [Perucca, 2010] Perucca E. When clinical trials make history: demonstrating efficacy of new antiepileptic drugs as monotherapy. Epilepsia. 2010;51:1933-1935.
  • [Perucca, 2012] Perucca E. What clinical trial designs have been used to test antiepileptic drugs and do we need to change them? Epileptic Disord. 2012;14:124-131.
  • [Perucca, 2018] Perucca E. From clinical trials of antiepileptic drugs to treatment. Epilepsia Open. 2018;3:220-230.
  • [Perucca and Crema, 1983] Perucca E., Crema A. Therapeutic monitoring of serum antiepileptic drug levels. Prog Clin Biol Res. 1983;124:267-283.
  • [Perucca and Wiebe, 2016] Perucca E., Wiebe S. Not all that glitters is gold: a guide to the critical interpretation of drug trials in epilepsy. Epilepsia Open. 2016;1:9-21.
  • [Perucca and Perucca, 2019] Perucca P., Perucca E. Identifying mutations in epilepsy genes: impact on treatment selection. Epilepsy Res. 2019;152:18-30.
  • [Pippenger et al., 1976] Pippenger C.E., Penry J.K., White B.G., Daly D.D., Buddington R. Interlaboratory variability in determination of plasma antiepileptic drug concentrations. Arch Neurol. 1976;33:351-355.
  • [Porter and Kupferberg, 2017] Porter R.J., Kupferberg H.J. The Anticonvulsant Screening Program of the National Institute of Neurological Disorders and Stroke, NIH: History and contributions to clinical care in the Twentieth century and beyond. Neurochem Res. 2017;42:1889-1893.
  • [Prunetti and Perucca, 2011] Prunetti P., Perucca E. New and forthcoming anti-epileptic drugs. Curr Opin Neurol. 2011;24:159-164.
  • [Ravizza and Vezzani, 2018] Ravizza T., Vezzani A. Pharmacological targeting of brain inflammation in epilepsy: Therapeutic perspectives from experimental and clinical studies. Epilepsia Open. 2018;3:133-142.
  • [Reynolds, 1975] Reynolds E.H. Chronic antiepileptic toxicity: a review. Epilepsia. 1975;16:319-352.
  • [Reynolds and Trimble, 1985] Reynolds E.H., Trimble M.R. Adverse neuropsychiatric effects of anticonvulsant drugs. Drugs. 1985;29:570-581.
  • [Rheims et al., 2011] Rheims S., Perucca E., Cucherat M., Ryvlin P. Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. Epilepsia. 2011;52:219-233.
  • [Richens, 1980] Richens A. Pharmacokinetics of anticonvulsant drugs. Acta Neurol Scand Suppl. 1980;80:40-45.
  • [Richens and Ahmad, 1975] Richens A., Ahmad S. Controlled trial of sodium valproate in severe epilepsy. Br Med J. 1975;4:255-256.
  • [Richens and Dunlop, 1975] Richens A., Dunlop A. Serum phenytoin levels in management of epilepsy. Lancet. 1975;2:247-248.
  • [Robert and Guibaud, 1982] Robert E., Guibaud P. Maternal valproic acid and congenital neural tube defects. Lancet. 1982;2:937.
  • [Rodin et al., 1974] Rodin E.A., Rim C.S., Rennick P.M. The effects of carbamazepine on patients with psychomotor epilepsy: results of a double-blind study. Epilepsia. 1974;15:547-561.
  • [Rowan et al., 2005] Rowan A.J., Ramsay R.E., Collins J.F. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology. 2005;64:1868-1873.
  • [Rowland, 1982] Rowland L.P. Introduction to first annual Merritt-Putnam symposium. Cambridge. Epilepsia. 2011;23:S1-4. Suppl. 1
  • [Ryvlin et al., 2011] Ryvlin P., Cucherat M., Rheims S. Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials. Lancet Neurol. 2011;10:961-968.
  • [Schiller and Buchtal, 1958] Schiller G., Buchtal F. Diphenylhydantoin and phenobarbital in serum in patients with epilepsy. Dan Med Bull. 1958;5:161-163.
  • [Shields and Saslow, 1983] Shields W.D., Saslow E. Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children. Neurology. 1983;33:1487-1489.
  • [Shorvon and Reynolds, 1977] Shorvon S.D., Reynolds E.H. Unnecessary polypharmacy for epilepsy. Br Med J. 1977;1:1635-1637.
  • [Shorvon et al., 1978] Shorvon S.D., Chadwick D., Galbraith A.W., Reynolds E.H. One drug for epilepsy. Br Med J. 1978;1:474-476.
  • [Sills and Brodie, 2009] Sills GJ, Brodie MJ. Antiepileptic drugs. Clinical drug development in epilepsy. In: Encyclopedia of Basic Epilepsy Research. Schwartzkroin P. Cambridge, MA: Academic Press, 2009: 1477-85.
  • [Tomson et al., 2019] Tomson T., Battino D., Perucca E. Teratogenicity of antiepileptic drugs. Curr Opin Neurol. 2019;32:246-252.
  • [White et al., 1966] White P.T., Plott D., Norton J. Relative anticonvulsant potency of primidone; a double blind comparison. Arch Neurol. 1966;14:31-35.